- Home
- IRON
IRON
Disc Medicine Inc.
as of 02-09-2026 4:00pm EST
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 3.0B | IPO Year: | N/A |
| Target Price: | $110.08 | AVG Volume (30 days): | 526.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.42 | EPS Growth: | N/A |
| 52 Week Low/High: | $30.82 - $99.50 | Next Earning Date: | 02-26-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -166028000.0 | FCF Growth: | N/A |
AI-Powered IRON Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Disc Medicine Inc. (IRON)
Chief Legal Officer
Avg Cost/Share
$69.74
Shares
1,000
Total Value
$69,740.00
Owned After
37,793
SEC Form 4
Chief Legal Officer
Avg Cost/Share
$78.52
Shares
6,500
Total Value
$511,471.76
Owned After
37,793
Director
Avg Cost/Share
$91.47
Shares
754
Total Value
$68,968.38
Owned After
14,013
Director
Avg Cost/Share
$91.24
Shares
68,923
Total Value
$6,288,534.52
Owned After
14,013
Director
Avg Cost/Share
$91.63
Shares
69,693
Total Value
$6,365,697.60
Owned After
14,013
Chief Medical Officer
Avg Cost/Share
$91.42
Shares
13,093
Total Value
$1,194,372.11
Owned After
76,002
Director
Avg Cost/Share
$92.81
Shares
45,507
Total Value
$4,204,407.26
Owned After
14,013
Chief Executive Officer
Avg Cost/Share
$92.45
Shares
40,000
Total Value
$3,721,931.19
Owned After
209,409
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Khara Rahul | IRON | Chief Legal Officer | Jan 20, 2026 | Sell | $69.74 | 1,000 | $69,740.00 | 37,793 | |
| Khara Rahul | IRON | Chief Legal Officer | Jan 2, 2026 | Sell | $78.52 | 6,500 | $511,471.76 | 37,793 | |
| Bitterman Kevin | IRON | Director | Dec 17, 2025 | Sell | $91.47 | 754 | $68,968.38 | 14,013 | |
| Bitterman Kevin | IRON | Director | Dec 16, 2025 | Sell | $91.24 | 68,923 | $6,288,534.52 | 14,013 | |
| Bitterman Kevin | IRON | Director | Dec 15, 2025 | Sell | $91.63 | 69,693 | $6,365,697.60 | 14,013 | |
| Savage William Jacob | IRON | Chief Medical Officer | Dec 15, 2025 | Sell | $91.42 | 13,093 | $1,194,372.11 | 76,002 | |
| Bitterman Kevin | IRON | Director | Dec 12, 2025 | Sell | $92.81 | 45,507 | $4,204,407.26 | 14,013 | |
| Quisel John D | IRON | Chief Executive Officer | Dec 11, 2025 | Sell | $92.45 | 40,000 | $3,721,931.19 | 209,409 |
Compare IRON vs Leading Stocks
See how IRON stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "IRON Disc Medicine Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.